99 related articles for article (PubMed ID: 21907091)
1. Animal models of tardive dyskinesia.
Kulkarni SK; Dhir A
Int Rev Neurobiol; 2011; 98():265-87. PubMed ID: 21907091
[TBL] [Abstract][Full Text] [Related]
2. Animal models of tardive dyskinesia--a review.
Kulkarni SK; Naidu PS
Indian J Physiol Pharmacol; 2001 Apr; 45(2):148-60. PubMed ID: 11480221
[TBL] [Abstract][Full Text] [Related]
3. Possible beneficial effect of peroxisome proliferator-activated receptor (PPAR)--α and γ agonist against a rat model of oral dyskinesia.
Grover S; Kumar P; Singh K; Vikram V; Budhiraja RD
Pharmacol Biochem Behav; 2013 Oct; 111():17-23. PubMed ID: 23948071
[TBL] [Abstract][Full Text] [Related]
4. Protective effect of rutin, a polyphenolic flavonoid against haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes.
Bishnoi M; Chopra K; Kulkarni SK
Fundam Clin Pharmacol; 2007 Oct; 21(5):521-9. PubMed ID: 17868205
[TBL] [Abstract][Full Text] [Related]
5. Protective effect of Curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain.
Bishnoi M; Chopra K; Kulkarni SK
Pharmacol Biochem Behav; 2008 Feb; 88(4):511-22. PubMed ID: 18022680
[TBL] [Abstract][Full Text] [Related]
6. Possible anti-oxidant and neuroprotective mechanisms of zolpidem in attenuating typical anti-psychotic-induced orofacial dyskinesia: a biochemical and neurochemical study.
Bishnoi M; Chopra K; Kulkarni SK
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1130-8. PubMed ID: 17513028
[TBL] [Abstract][Full Text] [Related]
7. Tardive dyskinesia: pathophysiology and animal models.
Casey DE
J Clin Psychiatry; 2000; 61 Suppl 4():5-9. PubMed ID: 10739324
[TBL] [Abstract][Full Text] [Related]
8. Drug therapies for tardive dyskinesia: Part 1.
Howland RH
J Psychosoc Nurs Ment Health Serv; 2011 Jun; 49(6):13-6. PubMed ID: 21598866
[TBL] [Abstract][Full Text] [Related]
9. Involvement of adenosinergic receptor system in an animal model of tardive dyskinesia and associated behavioural, biochemical and neurochemical changes.
Bishnoi M; Chopra K; Kulkarni SK
Eur J Pharmacol; 2006 Dec; 552(1-3):55-66. PubMed ID: 17064683
[TBL] [Abstract][Full Text] [Related]
10. Tardive dyskinesia: clinical presentation and treatment.
van Harten PN; Tenback DE
Int Rev Neurobiol; 2011; 98():187-210. PubMed ID: 21907088
[TBL] [Abstract][Full Text] [Related]
11. Comparative neurochemical changes associated with chronic administration of typical and atypical neuroleptics: implications in tardive dyskinesia.
Bishnoi M; Kumar A; Chopra K; Kulkarni SK
Indian J Exp Biol; 2007 Feb; 45(2):175-9. PubMed ID: 17375557
[TBL] [Abstract][Full Text] [Related]
12. Progesterone attenuates neuroleptic-induced orofacial dyskinesia via the activity of its metabolite, allopregnanolone, a positive GABA(A) modulating neurosteroid.
Bishnoi M; Chopra K; Kulkarni SK
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):451-61. PubMed ID: 17988775
[TBL] [Abstract][Full Text] [Related]
13. Co-administration of nitric oxide (NO) donors prevents haloperidol-induced orofacial dyskinesia, oxidative damage and change in striatal dopamine levels.
Bishnoi M; Chopra K; Kulkarni SK
Pharmacol Biochem Behav; 2009 Jan; 91(3):423-9. PubMed ID: 18789960
[TBL] [Abstract][Full Text] [Related]
14. Electron spin resonance spectroscopy reveals alpha-phenyl-N-tert-butylnitrone spin-traps free radicals in rat striatum and prevents haloperidol-induced vacuous chewing movements in the rat model of human tardive dyskinesia.
Rogoza RM; Fairfax DF; Henry P; N-Marandi S; Khan RF; Gupta SK; Mishra RK
Synapse; 2004 Dec; 54(3):156-63. PubMed ID: 15452862
[TBL] [Abstract][Full Text] [Related]
15. Clozapine in tardive dyskinesia: observations from human and animal model studies.
Tamminga CA; Thaker GK; Moran M; Kakigi T; Gao XM
J Clin Psychiatry; 1994 Sep; 55 Suppl B():102-6. PubMed ID: 7961550
[TBL] [Abstract][Full Text] [Related]
16. Distinguishing akathisia and tardive dyskinesia: a review of the literature.
Munetz MR; Cornes CL
J Clin Psychopharmacol; 1983 Dec; 3(6):343-50. PubMed ID: 6139392
[TBL] [Abstract][Full Text] [Related]
17. [Clinical aspects of tardive dyskinesias induced by neuroleptics].
Villeneuve A; Lajeunesse C
Encephale; 1988 Sep; 14 Spec No():209-14. PubMed ID: 2905648
[TBL] [Abstract][Full Text] [Related]
18. [Tardive dyskinesia: a review].
Crespo Facorro B; Payá González B; Ruiz Fernández V; Carbonell Masia C
Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1997; 25(2):118-27. PubMed ID: 9245189
[TBL] [Abstract][Full Text] [Related]
19. No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients.
Silver H; Geraisy N; Schwartz M
J Clin Psychiatry; 1995 Apr; 56(4):167-70. PubMed ID: 7713856
[TBL] [Abstract][Full Text] [Related]
20. Spontaneous and tardive dyskinesias: clinical and laboratory studies.
Casey DE
J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):42-7. PubMed ID: 2858480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
